57results about How to "Reduced gene expression" patented technology

The present invention provides novel anticode oligomers and methods of using them for controlling the growth of cancer cells expressing the bcl-2 gene.

The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

The present invention describes the production of L-tyrosine by culturing in a medium an Escherichia bacterium which has L-tyrosine-producing ability and which carries a mutant prephenate dehydrogenase which is desensitized to feedback inhibition by L-tyrosine, producing and accumulating L-tyrosine in the medium or in the bacterial cells, and collecting L-tyrosine from the medium or the bacterial cells.

The invention provides sgRNA and a gene vector for inhibiting bladder cancer by targeting human lncRNA-UCA1 and an application of the sgRNA; specifically, sgRNA sequences of an lncRNA-UCA1 gene and a PD-1 gene suitable for CRISPR-Cas9 targeted splicing are designed; by transforming plasmids of specific splicing lncRNA-UCA1 gene and CRISPR-Cas9 nuclease gene into human bladder cancer cells, the expression of the lncRNA-UCA1 gene drops so as to inhibit the growth of tumor cells; and the plasmid, together with a human PD-1 gene targeted knockout vector, is transformed into a humanized mouse model of bladder cancer transplanted tumor, so as to obviously inhibit the growth of tumors. According to the invention, the vector is simple in preparing steps, the sgRNA is good in targeting property and the CRISPR-Cas9 is high in knockout efficiency.

In some aspects, compositions and methods for identifying therapeutic targets for treatment of mitochondrial disorders are provided. In some aspects compositions and methods for identifying therapeutic agents for treatment of mitochondrial disorders. In some aspects, the disclosure identifies ATPIF1 as a therapeutic target for mitochondrial disorders.

The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.

The present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist of the preparation of a medicament for the treatment of skin ageing or wrinkling. Furthermore, the present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a cosmetic composition.

The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A₂, and even more particularly phospholipase A₂ derived from the snake venom of Naja sputatrix

The present invention relates to a method for processing a subject's genomic data comprising (a) obtaining a subject's genomic sequence; (b) reducing the complexity and/or amount of the genomic sequence information; and (c) storing the genomic sequence information of step (b) in a rapidly retrievable form. The present invention further relates to a method wherein the step of reducing the complexity and/or amount of the genomic sequence information is carried out by cropping said genomic sequence information except for signature data pertaining to a disease or disorder, or by aligning a subject's genomic sequence with a reference sequence comprising signature data pertaining to a disease or disorder. Furthermore, the invention relates to a method wherein the use of a subject's functional genetic information, in particular gene expression data is included, as well as to a method, wherein the information is encoded in matrices and decoded and represented based on Markov chain processes. The obtained information can also be used for diagnosing, detecting, monitoring or prognosticating a disease and/or for the preparation of a subject's molecular history. In addition, a corresponding clinical decision support and storage system, preferably in the form of an electronic picture/data archiving and communication system, is provided.

The invention belongs to the field of gene engineering, and relates to an improved promoter and application thereof. The improved promoter is used for mutating nucleotide sequences from a -35 area toa -10 area in a promoter region into recognition sites of endonuclease. The improved promoter can be used for solving the problem that the cloning cannot be achieved, which is caused as a transcription or translation product of an exogenous gene, which is promoted by a strong promoter existing in a vector adopting blue and white screening, possibly has toxicity to a host, can be used for avoidingthe defect that the vector loses 1bp to 2bp at an enzyme digestion site to cause the frame shift mutation of a lacZalpha gene to generate false positive cloning, and can be used for eliminating the false negative phenomenon that a plate all has locus ceruleus, which is caused as an extraneous DNA (Deoxyribonucleic Acid) fragment is smaller and moreover a reading frame of the lacZalpha gene is notchanged by the insertion of extraneous DNA.

The invention discloses rice metal-tolerant protein OsMPT1 as well as an encoding gene and an RNA (Ribonucleic Acid) interference segment thereof. The amino-acid sequence of the rice metal-tolerant protein OsMPT1 is shown as SEQ ID NO.2, the nucleotide sequence of the encoding gene OsMPT1 is shown as SEQ ID NO.1, and the gene is a key gene for responding cadmium stress, which has important significance for comprehensively understanding the biological function of metal-ion transport protein in a plant. The nucleotide sequence of the RNA interference segment for the rice metal-tolerant protein OsMPT1 is shown as SEQ ID NO.3, the expressing quantity of the OsMPT1 gene in the whole rice plant can be decreased after the RNA interference segment is expressed in rice by utilizing an expressing vector, and the heavy-metal cadmium-enriching quantity of rice seeds is also decreased along with the decrease of the expressing quantity of the OsMPT1 gene. The RNA interference segment for the rice metal-tolerant protein OsMPT1 disclosed by the invention can be applied to the gene-engineering inheritance breeding of the rice, rice varieties with low-absorption enriched cadmium are cultivated, andfood safety hazards brought to grain crops by heavy-metal cadmium are lightened.

The present invention relates to compounds of Formula I

or pharmaceutically acceptable salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as A2A inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer. The invention also relates to a process for manufacturing compounds of Formula I.

Protein complexes are provided comprising FHOS and one or more proteins selected from the group consisting of GROUP1. Methods of using the protein complexes in diagnosing diseases and disorders are also provided. In addition, the protein complexes are also useful in screening assays for identifying compounds effective in treating and/or preventing diseases and disorders associated with FHOS and its interactors.

Disclosed are methods for the treatment of proliferative disorders using compounds and/or environmental conditions which result in a difference in sensitivity of targeted and non-targeted cells. Certain of the methods involve the identification and use of allele-specific inhibitors of conditionally essential genes.

The invention belongs to the field of gene engineering and relates to a pre-T vector and a T vector composed of the pre-T vector and application thereof. The improved promoter is a recognition site for mutation from a nucleotide sequence from -35 region to -10 region in a promoter region into endonuclease. By the T vector, the problem that the product of transcription or translation of exogenous genes by a strong promoter during blue-white selection of a vector might be toxic to host and cloning will fail can be overcome, blue-white selection of a vector might be toxic to host as a strong promoter starts transcription or translation; the defect that delection of 1-2 bp at enzyme digestion site leads to lacZalpha gene frameshift mutation and false positive clones are generated can be avoided; and the false negative phenomenon that a plate is full of blue stains because exogenous DNA fragment is small and insertion of exogenous DNA does not change a reading frame of lacZalpha gene can beeliminated.

The transcription factor NF-κB is activated in response to various stimuli including ionizing radiation. Disruption of NFκB activation by mutant forms of the NF-κB inhibitor IκB-α or by proteasome inhibitors enhances both sensitivity to radiation and radiation-induced apoptasis. The present invention shows that expression of a dominant negative fragment of human p65 (p65DN) leads to down-regulation of both endogenous p65 protein and its mRNA. The dominant negative protein also inhibits radiation-induced NF-κB activation by preventing the proteolysis of IκB-α, resulting in enhancement of cellular radiosensitivity and radiation-induced apoptosis. The region of p65 in the dominant negative fragment is thus a molecular target for disruption of NF-κB activation and sensitization of tumors to radiotherapy.

The invention relates to an OsbHLH116 gene for controlling rice seed germination, an RNAi carrier, as well as a preparation method and application thereof, belonging to the technical field of plant gene engineering. The method comprises the following steps: designing an RNA interference fragment according to the coding sequence of gene OsbHLH116, performing primary digestion and linking on the interference fragment and a carrier pTCK303 to obtain an OsbHLH116-RNAi expression carrier; and transforming the rice variety Xinfeng No.2 by utilizing an agrobacterium-mediated method, and verifying the OsbHLH116 gene expression quantity in an RNAi transgenic line through qRT-PCR. Results indicate that the OsbHLH116 gene expression is remarkably reduced. Compared with a wild gene, the OsbHLH116-RNAi line has the advantage that the seed germination rate is remarkably reduced, and the OsbHLH116 gene is related to rice seed germination controlling.

The present invention relates to Production of transgenic tea (Camellia sinensis (L.) O. Kuntze) through biolistic

The invention relates to a cucumber CsLsi2 gene, a protein coded by the same and application of the cucumber CsLsi2 gene. The nucleotide sequence of the cucumber CsLsi2 gene is shown as SEQ ID NO: 1,and the sequence of the protein coded by the gene is shown as SEQ ID NO: 2. The cucumber CsLsi2 gene closely related to the cucumber bloom character is obtained by cloning after genome-wide association analysis and screening, the expression level of the gene is positively related to the cucumber bloom content, and early termination of amino acid translation is caused after the 754th basic group ofthe sequence, shown as SEQ ID NO: 1, of the cucumber gene is changed from C to T. Cloning and expression analysis of the cucumber CsLsi2 gene play a promoting role to a great extent in solving the problem that cucumber bloom gene resources are difficult to screen.

This document provides methods and materials for reducing venous stenosis formation of an arteriovenous fistula or graft. For example, methods and materials for using VEGF inhibitors to reduce venous stenosis formation of arteriovenous fistulas or grafts are provided.

The invention belongs to the field of genetic engineering and relates to an improved promoter and application of the improved promoter. According to the improved promoter, a nucleic acid sequence between a -35 zone and a -10 zone in the promoter is mutated into an endonuclease recognition site. By adopting the improved promoter, the problems that a vector obtained blue-white selection is adopted and has a transcription or translation product obtained by promoting an exogenous gene through a strong promoter, so that toxicity to a host is possibly caused and the host cannot be cloned are solved,and the defect that a lacZalpha gene has frameshift mutation to generate false positive cloning, caused by the fact that 1-2bp of the vector is deleted at an enzyme digestion site can be avoided; a condition that an exogenous DNA (Deoxyribonucleic Acid) segment is relatively small and a reading frame of the lacZalpha gene is not changed when exogenous DNA is inserted so that a false negative phenomenon that locus ceruleus is fully distributed on a flat plate can be eliminated.

The invention discloses application of a Pulsatilla chinensis decoction in drugs for reducing TLR-4 gene expression in intestinal microvascular endothelial cells. The Pulsatilla chinensis decoction comprises, by weight, 10-15 parts of Coptis chinensis, 5-15 parts of golden cypress, 15-30 parts of ash bark and 15-30 parts of Pulsatilla chinensis. The Pulsatilla chinensis decoction remarkably reduces the TLR-4 gene expression in the intestinal microvascular endothelial cells, and the effect is obvious.

The invention relates to the technical field of gene engineering, and particularly discloses application of a non-coding gene capable of controlling female ear thickness heterosis of corn and a precursor sequence of the non-coding gene. The non-coding gene is a zma-miR390 gene, wherein the RNA sequence of the non-coding gene is as shown in SEQ ID NO. 1, and the precursor RNA sequence of the non-coding gene is as shown in SEQ ID NO. 2. The zma-miR390 gene provided by the invention can be used for improving the female ear thickness and yield of corn, and provides help for breeding practice aiming to increase the yield of corn.

The present invention discloses functional food for intervening chronic alcohol-induced small intestine injury and an application of the functional food. An intervention effect of chitosan oligosaccharide on the chronic alcohol-induced small intestine injury is reflected by increasing length of intestinal villi, depth of a crypt and thickness of a muscular layer and also reflected by improving gene expression quantity of a tight junction protein Occludin, reducing gene expression quantity of Claudin4, reducing D-lactic acid content and diamine oxidase activity in plasma, and reducing malondialdehyde and protein carbonyl content, thereby alleviating oxidative damages of intestinal tissues caused by alcohol; at the same time the functional food can reduce expressions of small intestine inflammatory factors IL-6, IL-1-beta and TNF-alpha and thus reduce inflammatory reactions of the small intestine tissues caused by alcohol.

Disclosed herein are methods of producing plants with preferred levels of vegetative growth periods, flowering times, and resistance to stress and pathogens; and uses of such plants. The inventors have identified that the ANGUSTIFOLIA(AtAN)/CtBP gene is a major determinant of the carbon allocation between the Shikimate Pathway and the Salicylic Acid (SA) and Jasmonic Acid(JA)/Ethylene pathway. Plants with modulated growth periods, flowering times, and resistance to stress/pathogen characteristics, based on modulation of the expression or activity of the ANGUSTIFOLIA (ATAN)/CTBP gene, have divergent uses including pulp and paper production, bioproduct production, and as pathogen-resistant crops.